Health
Animal data supports efficacy of baricitinib vs SARS-COV-2 – News-Medical.Net
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 202…
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Inflammatory Responses in COVID-19
Severe COVID-19 is associated with high fever, non-…
-
Business20 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business16 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News15 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News15 hours agoQueen Street Mall to get a 3D digital billboard; Dutton dumps controversial plans to end flexible work; Measles alert for tourist hotspots